Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (RPRX), reported insider activity including the sale of 100,000 Class A Ordinary Shares by an associated entity, SCH Investment Partners LLC, at a weighted average price of $59.9725 per share. The sale was executed under a Rule 10b5-1 trading plan. Additionally, Hite made a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University, impacting his direct and indirect holdings in the company.
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity
Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, sold 100,000 Class A Ordinary Shares for approximately $5.99 million under a 10b5-1 trading plan. Additionally, he donated 16,800 shares to Lehigh University. Following these transactions, Hite retains significant direct and indirect ownership in the company.
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale
SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma (NASDAQ: RPRX) with an aggregate market value of $6,012,000. These shares were acquired in private transactions in 2024 and 2025 and represent a small fraction of Royalty Pharma's 445,277,344 outstanding shares. The planned sale is part of a pre-arranged selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c), and follows previous sales by SCH Investment Partners LLC in June 2026.
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated
Pablo Legorreta has updated his beneficial ownership in Royalty Pharma (NASDAQ: RPRX) through an amended SEC filing, reporting a stake of 101.8 million Class A shares, representing 18.73% of the class. This includes shares issuable under an A&R Exchange Agreement, and the recalculation follows a change in the number of outstanding Class A shares. The filing also details recent equity transactions, including the acquisition of shares from performance awards and a gift of partnership interests.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares totaling $645,551 on August 13, 2026, under a Rule 10b5-1 trading plan. The shares were sold in multiple transactions at prices ranging from $57.99 to $59.52. Despite this insider sale, Royalty Pharma recently reported strong Q2 2026 results with increased royalty receipts and a raised full-year outlook, leading BofA Securities to increase its price target.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares totaling $645,551 through a Rule 10b5-1 trading plan. The sales occurred on August 13, 2026, with shares trading near their 52-week high. Despite the sales, Coyne retains significant direct and indirect holdings in the company.
Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan
Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 11,002 Class A Ordinary Shares of RPRX on August 13, 2026, through a Rule 10b5-1 plan. The sales were executed in two blocks at weighted average prices of $58.5864 and $59.1415, totaling approximately $646K. Following these transactions, Coyne retains significant indirect holdings, including shares in IRAs and exchangeable interests in limited partnerships.
RPRX (RPRX) investor files to sell 125,000 Class A shares on NASDAQ
A shareholder of Royalty Pharma plc (RPRX) has filed a Form 144 to sell 125,000 Class A ordinary shares on NASDAQ through J.P. Morgan Securities LLC, with an indicated aggregate market value of $7,223,750. The filing, dated August 12, 2026, notes the planned sale is related to a conversion of LP Interests on August 7, 2026. This potential sale represents a small fraction of the 445,277,344 Class A ordinary shares outstanding.
Royalty Pharma (RPRX) files to potentially sell 11.9M Class A shares
Royalty Pharma plc (RPRX) has filed a Form 144 notice indicating a proposed sale of up to 11,925,082 Class A ordinary shares through J.P. Morgan Securities LLC on NASDAQ. These shares were acquired through various means, including a significant block from a Conversion of LP Interests and multiple compensation grants from the issuer dating back to 2021. The filing provides detailed figures on the share blocks and the acquisition dates, clarifying the nature of the transaction.
Royalty Pharma (RPRX) CEO gets share award and gifts partnership interests
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma (RPRX), received an exempt award of 65,216 Class A Ordinary Shares as settlement for Equity Performance Awards, increasing his direct holdings to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares. The filing details his substantial direct and indirect holdings, including exchangeable Class B and Class E shares held through family entities and trusts.
Royalty Pharma (RPRX) EVP gets 8,252 shares, gifts LP interests
Royalty Pharma EVP Urist Marshall received 8,252 Class A Ordinary Shares as an exempt award and gifted 3,000 limited partnership interests, which are exchangeable into 30,000 Class A shares. Marshall also holds indirect Class A shares through an IRA and Class E Ordinary Shares exchangeable into over 1.3 million additional Class A shares. These transactions were reported via an SEC Form 4 filing.
Royalty Pharma plc (RPRX) CFO logs equity award and 18,500-share gift
Royalty Pharma plc CFO Terrance P. Coyne reported an acquisition of 11,002 Class A Ordinary Shares through an exempt settlement of Equity Performance Awards and an indirect bona fide gift of 18,500 Class E Ordinary Shares. Following the gift, Coyne indirectly holds 1,788,777 Class E shares, which are subject to vesting and convertible into Class A shares. Additionally, Coyne and related entities maintain significant holdings, including limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares.
Royalty Pharma (NASDAQ: RPRX) EVP gets 11,002-share Class A equity award
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (NASDAQ: RPRX), was awarded 11,002 Class A Ordinary Shares on August 5, 2026, as part of an exempt grant connected to the settlement of Equity Performance Awards. This transaction increased the indirect holdings through SCH Investment Partners LLC to 470,401 shares, while Hite also directly holds 40,000 Class A Ordinary Shares. Additionally, family vehicles controlled by Hite hold interests exchangeable into over 2 million more Class A Ordinary Shares.
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD
This article provides a revenue breakdown for Royalty Pharma Plc Class A (HAM:RPD). It highlights that in the last year, the company generated 2.77 billion EUR, with the Biopharmaceutical Royalties segment being the top performer, contributing 2.02 billion EUR. The United States was identified as the greatest contributor by region, also accounting for 2.02 billion EUR.
Total equity of Royalty Pharma Plc Class A – HAM:RPD
This article displays the total equity of Royalty Pharma Plc Class A (HAM:RPD) on the Hamburg Stock Exchange. It provides a snapshot of the company's financials through TradingView, indicating that the market was closed with no trades at the time of viewing. The content confirms the article is about financial data for Royalty Pharma Plc Class A.
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD
Royalty Pharma Plc Class A (HAM:RPD) generated €2.77 billion in revenue last year, primarily from its Biopharmaceutical Royalties segment, which accounted for €2.02 billion. The United States was the largest contributor to this revenue, also bringing in €2.02 billion. This data provides a breakdown of the company's top-performing segments and geographical contributions.
Royalty Pharma Plc Class A Revenue Breakdown – TRADEGATE:RPD
Royalty Pharma Plc Class A (RPD) generated €2.77 billion in revenue last year, with its Biopharmaceutical Royalties segment contributing the most at €2.02 billion. The United States was the largest regional contributor, also bringing in €2.02 billion. This data highlights the company's key revenue drivers and geographic focus.
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
Royalty Pharma has acquired a royalty interest in AstraZeneca's cliramitug from Neurimmune for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 TTR-fibril-depleting antibody for TTR amyloidosis with cardiomyopathy (ATTR-CM), a rapidly growing market. This investment targets a significant unmet medical need and supports Neurimmune's R&D pipeline.
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share
Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation in the sector, holding royalties on over 35 commercial products and 19 development-stage candidates. This dividend announcement reflects strong financial health and a commitment to shareholder value, though it also raises questions about reinvestment opportunities and future strategic plans.
Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders
Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry.
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share
Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation in the sector. Its portfolio includes royalties from over 35 commercial products and 19 development-stage candidates.
Royalty Pharma declares $0.235 dividend for Q3 2026, payable September 10
Royalty Pharma plc has declared a dividend of $0.235 per Class A ordinary share for the third quarter of 2026. This dividend is scheduled to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. The announcement highlights the company's consistent strategy of returning value to its shareholders, supported by its significant portfolio of biopharmaceutical royalties.
ETFs Investing in Royalty Pharma Plc Class A Stocks
This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover a range of investment focuses, from diversified total market funds to sector-specific and ESG-focused options.
Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades
Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additional 461,953 shares held indirectly through SCH Investment Partners LLC.
[Form 4] Royalty Pharma plc Insider Trading Activity
Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Urist directly holds no Class A shares but maintains an indirect holding of 19,020 shares through an IRA.
Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M
Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted on May 8, 2026, as part of the company's equity compensation program. While the sales don't explicitly link to the award, the various transactions relate to Urist's holdings.
[144] Royalty Pharma plc SEC Filing
This article reports a Form 144 SEC filing by Royalty Pharma plc (RPRX), indicating a proposed sale of 100,000 Class A Ordinary Shares with an aggregate market value of $5,709,000. These shares were acquired from the issuer in a private transaction on February 14, 2025. The filing, accepted by the SEC on July 1, 2026, also details the securities exchange as NASDAQ.
Royalty Pharma (RPRX) director gets equity grant in lieu of cash
Royalty Pharma (RPRX) director Bonnie L. Bassler received an equity grant of 689 Class A Ordinary Shares as compensation, valued at $37,500, in lieu of a quarterly cash retainer. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan, with each share valued at $54.3998. Following this transaction, Bassler directly holds 79,181 Class A Ordinary Shares, highlighting a non-cash compensation method rather than an open-market purchase or sale.
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD
The article mentions the enterprise value to revenue forward for Royalty Pharma Plc Class A, traded on the Stuttgart Stock Exchange under the symbol RPD. It is a financial data point for the company in the Pharmaceuticals: Major industry within Health Technology. The content provided is minimal and appears to be a stub or a section of a larger financial information display, highlighting the period and value change.
Price to earnings forward of Royalty Pharma Plc Class A – SWB:RPD
This article provides access to the "Price to earnings forward" financial metric for Royalty Pharma Plc Class A (SWB:RPD) on TradingView. It indicates that the market for this stock was closed with no trades at the time of access. The primary content focuses on directing users to financial data for the company.
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan
An entity linked to Christopher Hite, EVP and Chairman, Partnering at Royalty Pharma plc, sold 150,000 Class A Ordinary Shares in open-market transactions on June 23, 2026. These sales, executed at weighted average prices around $54, were pre-planned under a Rule 10b5-1 trading plan adopted in March 2026. Following these transactions, Hite and the associated entity still retain a substantial holding of Royalty Pharma shares.
Form 4 Royalty Pharma Plc For: 25 June By Investing.com
This article provides details of a Form 4 filing for Royalty Pharma Plc on June 25, 2026. Form 4 filings typically report changes in beneficial ownership of securities by company insiders. The article also includes current market data for various indices, commodities, and currencies.
Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan
Royalty Pharma EVP Marshall Urist sold 9,098 Class A Ordinary Shares at a weighted average price of $55.1843 per share, totaling over $502,000, under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following this transaction, Urist directly holds 9,099 shares. The sale reinforces that such planned trades are not based on immediate insider information.
Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX)
This article provides an overview of Royalty Pharma plc (NASDAQ: RPRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings per share and revenue, and key metrics like market capitalization, EBITDA, and dividend yield, advising readers to conduct their own research.
Form 144 Royalty Pharma plc For: 24 June By Investing.com
This article from Investing.com is a brief report about Royalty Pharma plc's Form 144 filing for June 24. It includes the ticker symbol RPRX which showed a slight increase of 0.76%. The content consists mostly of market data, indices, commodity prices, and other financial performance indicators for various companies and markets.
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX)
Marshall Urist, an insider at Royalty Pharma plc (NASDAQ: RPRX), reported selling 13,684 shares on May 14, 2026, for $726,137.82 and another 13,684 shares on May 20, 2026, for $721,837.21. These transactions were disclosed in a Form 144 SEC filing, which also noted an Equity Performance Award of 9,098 shares granted on May 8, 2026. The filing provides details on the nature of these transactions and the associated financial figures.
[144] Royalty Pharma plc SEC Filing
Royalty Pharma plc (RPRX) has filed a Form 144 with the SEC, indicating a proposed sale of 30,000 Class A Ordinary Shares by an individual who acquired them through a purchase in an IPO's reserved shares program on June 18, 2020. The aggregate market value of these shares is $1,660,500, with the sale scheduled for June 23, 2026, on NASDAQ through Merrill Lynch. The filing confirms no material adverse information is known by the seller that has not been publicly disclosed.
[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed Amendment No. 8 to their Schedule 13D for Royalty Pharma plc, indicating their beneficial ownership has decreased to 4.8% of outstanding Class A shares, below the 5% threshold. This filing acts as a final "exit" amendment, relieving them of further Schedule 13D reporting obligations for Royalty Pharma. The report details the trust and fund structures through which the shares are held and disclaims beneficial ownership by associated individuals.
Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant
Royalty Pharma director Gregory Norden was awarded 4,545 Class A Ordinary Shares in restricted stock units (RSUs) on June 5, 2026, as an equity grant under the company’s 2020 Independent Director Equity Incentive Plan. The RSUs have a grant price of $0.00 per share and are set to vest 100% on the earlier of one year from the grant date or the next annual shareholders’ meeting. Following this transaction, Norden directly holds 196,348 Class A Ordinary Shares.
Royalty Pharma (RPRX) director receives 4,545 share unit award
Royalty Pharma plc director Elizabeth H. Weatherman was granted an equity award of 4,545 restricted stock units, which are Class A Ordinary Shares. This compensation-related award, at no cash cost, will vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this transaction, Weatherman directly holds 13,103 shares.
Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX)
Royalty Pharma director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). These RSUs, granted under the company's 2020 Independent Director Equity Incentive Plan, generally vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this grant, Love directly holds 58,393 Class A Ordinary Shares in Royalty Pharma (RPRX).
Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant
Royalty Pharma plc director David C. Hodgson received a grant of 4,545 restricted stock units (RSUs) tied to Class A ordinary shares as equity compensation. These RSUs, awarded under the company's 2020 Independent Director Equity Incentive Plan, will vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Hodgson holds these units solely for the benefit of General Atlantic Service Company, L.P., disclaiming personal beneficial ownership.
Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan
Royalty Pharma plc (RPRX) director Vlad Coric was granted 4,545 Restricted Stock Units (RSUs) at no cost under the company's 2020 Independent Director Equity Incentive Plan. These RSUs will vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this award, Coric directly holds 15,343 Class A Ordinary Shares.
Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares
Royalty Pharma plc director Carole Ho was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units as compensation. The award, valued at $0.00 per share, is set to vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this transaction, Ho directly holds 4,545 shares and indirectly holds 8,558 shares through a family trust.
Royalty Pharma (RPRX) awards 4,545 RSUs to board director
Royalty Pharma (RPRX) reported that its director, Catherine M. Engelbert, received an award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). This award was granted under the company’s 2020 Independent Director Equity Incentive Plan at no cash cost to her. Following this transaction, Engelbert directly holds a total of 55,673 Class A Ordinary Shares, with the RSUs scheduled to vest on the earlier of one year from the grant date or the next annual shareholders' meeting.
Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares
Royalty Pharma (RPRX) director Bonnie L. Bassler was granted 4,545 restricted stock units (RSUs) as part of her compensation, increasing her direct holdings to 78,492 Class A Ordinary Shares. This award, made under the company's 2020 Independent Director Equity Incentive Plan, vests 100% on the earlier of one year from the grant date or the next annual shareholder meeting. The transaction is a routine, non-cash compensation grant rather than an open-market purchase or sale.
Cash from operating activities of Royalty Pharma Plc Class A – XETR:RPD
The article focuses on the "Cash from operating activities" for Royalty Pharma Plc Class A, traded on XETRA under the symbol RPD. It presents a data table showing the period, value, change, and percentage change for this financial metric. The content underscores the financial overview of Royalty Pharma Plc Class A on the TradingView platform.
Royalty Pharma (RPRX) shareholders back directors, pay and share issuance powers at 2026 AGM
Royalty Pharma plc shareholders approved all proposals at its 2026 Annual General Meeting, with a strong quorum of 88.08% voting power. Key approvals included the election of all nine director nominees, executive compensation on a non-binding basis, and the ratification and re-appointment of Ernst & Young as auditors. Shareholders also granted the board authority for potential share repurchases and for allotting shares, including without pre-emption rights, indicating broad support for the company's governance and financial flexibility.
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)
This article provides a comprehensive overview of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) stock, including its current price, performance metrics, and key statistics such as market cap, P/E ratio, and dividend yield. It also covers technical and fundamental analysis ratings from ChartMill, recent earnings reports, analyst forecasts, and company details, highlighting its business model of funding biopharmaceutical innovation through royalties.
Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale occurred near the stock's 52-week high, with the company showcasing strong Q1 2026 financial performance. Despite the sale, Coyne retains significant direct and indirect holdings in Royalty Pharma.
